- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01544673
Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males
April 26, 2012 updated by: Pfizer
An Open-label, Placebo-controlled Phase 1 Study to Evaluate the Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Male Subjects
Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear.
This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and monocytes) in healthy subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects between the ages of 20 and 45 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement and clinical laboratory tests).
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria:
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- Subject who had a bacterial/viral infection within 2 weeks prior to the first dose of study medication.
- Subjects with current or prior neutropenia (eg, <1.4 x 109 neutrophils /L).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm B
|
500 mg oral placebo twice daily for 4.5 days
|
Active Comparator: Arm A
|
600 mg oral tablet twice daily for 4.5 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in phagocytosis of gram-negative bacteria by neutrophils
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Change from baseline in phagocytosis of gram-negative bacteria by monocytes
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Change from baseline in interleukin-1 receptor antagonist secretion in response to lipopolysaccharide stimulation
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Change from baseline in interleukin-1-beta secretion in response to lipopolysaccharide stimulation
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Change from baseline in interleukin-6 secretion in response to lipopolysaccharide stimulation
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Change from baseline in interleukin-8 secretion in response to lipopolysaccharide stimulation
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Change from baseline in tumor necrosis factor alpha secretion in response to lipopolysaccharide stimulation
Time Frame: Baseline, day 4 and day 5
|
Baseline, day 4 and day 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Linezolid peak concentration on day 4
Time Frame: day 4
|
day 4
|
Linezolid peak concentration on day 5
Time Frame: day 5
|
day 5
|
Linezolid trough concentration on day 5
Time Frame: day 5
|
day 5
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
April 1, 2012
Study Completion (Actual)
April 1, 2012
Study Registration Dates
First Submitted
February 29, 2012
First Submitted That Met QC Criteria
February 29, 2012
First Posted (Estimate)
March 6, 2012
Study Record Updates
Last Update Posted (Estimate)
April 30, 2012
Last Update Submitted That Met QC Criteria
April 26, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A5951164
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gram Positive Infection
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
Cubist Pharmaceuticals LLCCompleted
-
Merck Sharp & Dohme LLCCompletedGram-Positive InfectionsUnited States, Bulgaria, Colombia, Norway, United Kingdom
-
Melinta Therapeutics, LLCRecruitingGram Positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Imperial College LondonHammersmith Hospitals NHS TrustCompletedStaphylococcal Infections | Gram-positive Bacterial InfectionsUnited Kingdom
-
Cubist Pharmaceuticals LLCCompletedGram Positive Infection | Concurrent Antibiotic TreatmentUnited States
-
Cumberland PharmaceuticalsCompletedBurns | Ulcer | Abscess | Cellulitis | Wound Infections | Infections, Gram-Positive BacterialUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut PasteurCompletedClostridium InfectionFrance
-
Marin L. Schweizer, PhDUniversity of Pennsylvania; Washington University School of Medicine; University... and other collaboratorsActive, not recruitingStaphylococcus Aureus InfectionUnited States
Clinical Trials on linezolid
-
PfizerCompletedVancomycin Resistance Enterococcus Faecium
-
Mabwell (Shanghai) Bioscience Co., Ltd.Recruiting
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
October 6 UniversityBeni-Suef UniversityRecruiting
-
PfizerCompletedMethicillin Resistant Staphylococcus Aureus (MRSA)United States, Greece, Colombia, Korea, Republic of, Russian Federation, Turkey, Brazil, Chile, Taiwan, Mexico, Belgium, Spain, Hong Kong, Puerto Rico, France, United Kingdom, Malaysia, Germany, South Africa, Portugal, Argentina, ...
-
Furiex Pharmaceuticals, IncCompletedComplicated Skin and Skin Structure InfectionsUnited States
-
PfizerCompleted
-
WockhardtCompletedAcute Bacterial Skin and Skin Structure InfectionsIndia
-
PfizerCompletedInfections, NosocomialJapan
-
PfizerCompletedGram-Positive Bacterial Infections | Skin and Connective Tissue Diseases